Impact of Incidental Germline BRCA1/2 and PALB2 Alterations on EGFR Monotherapy Real-World Outcomes for Patients With Advanced Non–Small-Cell Lung Cancer
Clinical Lung Cancer · 2025
DOI: 10.1016/j.cllc.2025.07.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Chetan V Vakkalagadda und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology/Oncology, School of Medicine, Oregon Health and Science University, Portland, OR; Department of Medici…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, BRCA1 Protein, Lung Neoplasms, Fanconi Anemia Complementation Group N Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Several studies have sought to determine the prevalence of BRCA1/BRCA2 in patient populations, but few have studied impacts of such alterations on patient outcomes beyond breast, ovarian, prostate and pancreatic cancers. This study assessed patient outcomes from a large real-world evidence (RWE) database for patients with EGFR-mutated advanced non-small-cell lung cancer (aNSCLC) who also had incidental pathogenic germline variants (iPGVs) in BRCA1, BRCA2 or PALB2 identified by a well-validated liquid biopsy. MATERIALS AND METHODS: Outcomes from patients included in GuardantINFORM, a RWE database, from Oct 2018-June 2024 with a diagnosis of aNSCLC and an incidental pathogenic germline variant (iPGV) in BRCA1/2 or PALB2 included in OncoKB treated with EGFR monotherapy (gBRCA/PALB2+) were matched in 1:5 using coarsened exact matching to a control cohort without iPGVs (control). Real-world time to treatment discontinuation (rwTTD) and real-world time to next treatment (rwTTNT) were used as proxies for PFS in months. Real-world overall survival (rwOS) was also assessed in months. RESULTS: 106 gBRCA+ patients were matched with 534 control patients for analysis. gBRCA/PALB2+ had numerically shorter rwTTD/rwTTNT (rwTTD: 11.5 vs. 13.9 months, P = .22; rwTTNT: 25.8 months vs. 32.1 months; P = .43). rwOS was 71.4 months for the gBRCA/PALB2+ group whereas the control group had a median of 57.4 months; limited-follow up reduced events available for analysis. DISCUSSION: Patients with gBRCA/PALB2+ aNSCLC treated with EGFR monotherapy may have subpar outcomes compared with control cohorts. Further research is required to understand the validity of this finding and inform clinical trial development for dual-target inhibition and/or patient selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Hematology/Oncology, School of Medicine, Oregon Health and Science University, Portland, OR; Department of Medicine, Division of Hematology/Oncology, Northwestern University, Chicago,…
- Medical Affairs and Outcomes and Evidence, Guardant Health, Redwood City, CA.
- Department of Medicine, Division of Hematology/Oncology, Northwestern University, Chicago, IL; Tempus AI, Tempus, Chicago, IL.
Zitieren
APA
Vakkalagadda, C. V., Bucheit, L., Clemens, K., Saha, J., Zhang, N., & Patel, J. D. (2025). Impact of Incidental Germline BRCA1/2 and PALB2 Alterations on EGFR Monotherapy Real-World Outcomes for Patients With Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.07.007
Vancouver
Vakkalagadda CV, Bucheit L, Clemens K, Saha J, Zhang N, Patel JD. Impact of Incidental Germline BRCA1/2 and PALB2 Alterations on EGFR Monotherapy Real-World Outcomes for Patients With Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2025.07.007
BibTeX
@article{Vakkalagadda2025,
author = {Vakkalagadda, Chetan V and Bucheit, Leslie and Clemens, Keelia and Saha, Jayati and Zhang, Nicole and Patel, Jyoti D},
title = {Impact of Incidental Germline BRCA1/2 and PALB2 Alterations on EGFR Monotherapy Real-World Outcomes for Patients With Advanced Non–Small-Cell Lung Cancer},
journal = {Clinical Lung Cancer},
year = {2025},
doi = {10.1016/j.cllc.2025.07.007}
}
EUVIMED